129 related articles for article (PubMed ID: 22383336)
1. Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study.
Dietrich H; Hu K; Ruffin M; Song D; Bouillaud E; Wang Y; Hasskarl J
Eur J Endocrinol; 2012 May; 166(5):821-8. PubMed ID: 22383336
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study.
Chen X; Shen G; Jiang J; Liu H; Hu K; Darstein C; Lasher J; Hu P
Clin Ther; 2014 Aug; 36(8):1196-210. PubMed ID: 25012727
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study.
Wolin EM; Hu K; Hughes G; Bouillaud E; Giannone V; Resendiz KH
Cancer Chemother Pharmacol; 2013 Aug; 72(2):387-95. PubMed ID: 23765178
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study.
Petersenn S; Bollerslev J; Arafat AM; Schopohl J; Serri O; Katznelson L; Lasher J; Hughes G; Hu K; Shen G; Reséndiz KH; Giannone V; Beckers A
J Clin Pharmacol; 2014 Nov; 54(11):1308-17. PubMed ID: 24800725
[TBL] [Abstract][Full Text] [Related]
5. Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study.
Beglinger C; Hu K; Wang Y; Bouillaud E; Darstein C; Wang Y; Mohideen P
Endocrine; 2012 Oct; 42(2):366-74. PubMed ID: 22527887
[TBL] [Abstract][Full Text] [Related]
6. Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.
Petersenn S; Unger N; Hu K; Weisshaar B; Zhang Y; Bouillaud E; Reséndiz KH; Wang Y; Mann K
J Clin Pharmacol; 2012 Jul; 52(7):1017-27. PubMed ID: 21673137
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Safety of Long-Acting Release Formulations of Pasireotide (SOM230) in a Male Population Who Are Hyperendemic Hepatitis B/C and Chronic Kidney Disease: An Open-Label, Phase I Study.
Huang CJ; Lu CH; Shih KC
Eur J Drug Metab Pharmacokinet; 2023 Nov; 48(6):665-674. PubMed ID: 37751056
[TBL] [Abstract][Full Text] [Related]
8. Tolerability and dose proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study.
Petersenn S; Hu K; Maldonado M; Zhang Y; Lasher J; Bouillaud E; Wang Y; Mann K; Unger N
Clin Ther; 2012 Mar; 34(3):677-88. PubMed ID: 22364824
[TBL] [Abstract][Full Text] [Related]
9. Combination of pasireotide and octreotide: effects on GH and IGF-I secretion and glucose metabolism in healthy volunteers.
Tauchmanova L; Breitschaft A; Holder G; Han KT; Choudhury S; Darstein C; Paul M; Drutinus E; Gericke G; Schmid HA; Pedroncelli AM
Endocrine; 2022 Feb; 75(2):537-548. PubMed ID: 34741720
[TBL] [Abstract][Full Text] [Related]
10. An open-label dose-escalation study of once-daily and twice-daily pasireotide in healthy volunteers: safety, tolerability, and effects on glucose, insulin, and glucagon levels.
Shenouda M; Maldonado M; Wang Y; Bouillaud E; Hudson M; Nesheiwat D; Hu K
Am J Ther; 2014; 21(3):164-73. PubMed ID: 22713526
[TBL] [Abstract][Full Text] [Related]
11. A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers.
Golor G; Hu K; Ruffin M; Buchelt A; Bouillaud E; Wang Y; Maldonado M
Drug Des Devel Ther; 2012; 6():71-9. PubMed ID: 22573933
[TBL] [Abstract][Full Text] [Related]
12. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.
Kvols LK; Oberg KE; O'Dorisio TM; Mohideen P; de Herder WW; Arnold R; Hu K; Zhang Y; Hughes G; Anthony L; Wiedenmann B
Endocr Relat Cancer; 2012 Oct; 19(5):657-66. PubMed ID: 22807497
[TBL] [Abstract][Full Text] [Related]
13. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study.
Fleseriu M; Rusch E; Geer EB;
Endocrine; 2017 Jan; 55(1):247-255. PubMed ID: 27896545
[TBL] [Abstract][Full Text] [Related]
15. How to Position Pasireotide LAR Treatment in Acromegaly.
Coopmans EC; Muhammad A; van der Lely AJ; Janssen JAMJL; Neggers SJCMM
J Clin Endocrinol Metab; 2019 Jun; 104(6):1978-1988. PubMed ID: 30608534
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.
Ferolla P; Brizzi MP; Meyer T; Mansoor W; Mazieres J; Do Cao C; Léna H; Berruti A; Damiano V; Buikhuisen W; Grønbæk H; Lombard-Bohas C; Grohé C; Minotti V; Tiseo M; De Castro J; Reed N; Gislimberti G; Singh N; Stankovic M; Öberg K; Baudin E
Lancet Oncol; 2017 Dec; 18(12):1652-1664. PubMed ID: 29074099
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of a pasireotide subcutaneous depot (CAM4071) and comparison with immediate and long-acting release pasireotide.
Johnsson M; Pedroncelli AM; Hansson A; Tiberg F
Endocrine; 2024 Feb; ():. PubMed ID: 38421556
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study.
Tahara S; Murakami M; Kaneko T; Shimatsu A
Endocr J; 2017 Jul; 64(7):735-747. PubMed ID: 28592706
[TBL] [Abstract][Full Text] [Related]
19. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
Bronstein MD; Fleseriu M; Neggers S; Colao A; Sheppard M; Gu F; Shen CC; Gadelha M; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Freda P;
BMC Endocr Disord; 2016 Apr; 16():16. PubMed ID: 27039081
[TBL] [Abstract][Full Text] [Related]
20. Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR.
Samson SL
Drugs; 2016 Sep; 76(13):1235-1243. PubMed ID: 27473537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]